Collaborations with 23andMe Therapeutics can take many different forms.
23andMe is actively seeking strategic alternatives to advance our immuno-oncology clinical assets, either as monotherapies or in combination with their existing pipeline programs.
Please contact bd@23andme.com for more information
23andMe is actively seeking strategic alternatives to advance our preclinical antibody programs addressing unmet medical needs in several immune-related conditions.
Please contact bd@23andme.com for more information